Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 8/20 | 0.52 |
| ▸ | MEN1 | O00255 | 7/20 | 0.52 |
| ▸ | LPAR1 | Q92633 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4417179 | 0.87 | KMT2A (0.47) | KMT2AMEN1LPAR1ALDH1A1KDM4E | |
| SCHEMBL13077829 | 0.82 | EPHX2 (0.53) | KMT2AMEN1ALDH1A1KDM4EHPGD | |
| SCHEMBL13077828 | 0.79 | EPHX2 (0.56) | ALDH1A1HTTLMNA | |
| SCHEMBL13077918 | 0.79 | EPHX2 (0.51) | ALDH1A1HTTLMNA | |
| SCHEMBL13078019 | 0.79 | EPHX2 (0.51) | ALDH1A1HTTLMNA | |
| SCHEMBL13077957 | 0.79 | EPHX2 (0.47) | KMT2AHTTLMNA | |
| SCHEMBL13077569 | 0.78 | MEN1 (0.48) | KMT2AMEN1LPAR1ALDH1A1KDM4E | |
| SCHEMBL13077619 | 0.77 | EPHX2 (0.44) | KMT2AMEN1HPGDHTTLMNA | |
| SCHEMBL13077961 | 0.77 | ADRA2C (0.48) | KMT2AMEN1HTT | |
| SCHEMBL13077821 | 0.76 | EPHX2 (0.45) | HTTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100279936-A1 | SUBSTITUTED ACETYLENIC COMPOUNDS USEFUL FOR THE TREATMENT OF DISEASES | LEO PHARMA A/S (DK) | 2010-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100279936-A1 | SUBSTITUTED ACETYLENIC COMPOUNDS USEFUL FOR THE TREATMENT OF DISEASES | C1R, C3AR1, PTH1R | KMT2A 4121/4885MEN1 202/4885LPAR1 325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.